Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
38.06
-0.43 (-1.12%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Celldex Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 35.73 | 28.87 | 28.36 | 34.81 | 29.43 | 39.14 |
Short-Term Investments | 415.73 | 489.7 | 696.93 | 388.78 | 275.52 | 369.11 |
Cash & Short-Term Investments | 451.46 | 518.57 | 725.28 | 423.6 | 304.95 | 408.25 |
Cash Growth | -32.95% | -28.50% | 71.22% | 38.91% | -25.30% | 109.98% |
Accounts Receivable | 0.23 | 2.02 | 0.7 | 2.63 | 0.35 | 0.17 |
Other Current Assets | 7.53 | 14.08 | 21.18 | 5.47 | 12.39 | 2.42 |
Total Current Assets | 459.22 | 534.66 | 747.16 | 431.69 | 317.69 | 410.84 |
Net Property, Plant & Equipment | 9.41 | 7.77 | 8.24 | 6.64 | 7.75 | 6.52 |
Other Intangible Assets | 27.19 | 27.19 | 27.19 | 27.19 | 27.19 | 27.19 |
Other Long-Term Assets | 15.43 | 13.36 | 9.75 | 0.11 | 0.1 | 0.1 |
Total Assets | 511.25 | 582.98 | 792.34 | 465.63 | 352.74 | 444.65 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 10.36 | 1.18 | 3.27 | 3.49 | 3.34 | 1.23 |
Accrued Expenses | 38.42 | 47.03 | 33.84 | 22.03 | 12.84 | 12 |
Current Portion of Long-Term Debt | 1.23 | 1.23 | 0.94 | 3.99 | 0.99 | 1.55 |
Current Portion of Leases | 1.47 | 1.55 | 1.45 | 1.61 | 1.45 | 1.75 |
Total Current Liabilities | 51.47 | 50.99 | 39.5 | 31.13 | 18.61 | 16.53 |
Long-Term Leases | 0.44 | 0.78 | 2.36 | 0.93 | 2.59 | 1.3 |
Other Long-Term Liabilities | 3.11 | 4.04 | 3.47 | 4.4 | 5.33 | 7.35 |
Total Long-Term Liabilities | 3.56 | 4.83 | 5.83 | 5.33 | 7.92 | 8.65 |
Total Liabilities | 55.03 | 55.82 | 45.34 | 36.46 | 26.53 | 25.18 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.07 | 0.07 | 0.07 | 0.06 | 0.05 | 0.05 |
Additional Paid-in Capital | 2,346 | 2,337 | 2,299 | 1,823 | 1,581 | 1,561 |
Accumulated Other Comprehensive Income | 2.52 | 3.63 | 3.31 | 3.31 | 1.26 | 1.89 |
Retained Earnings | -1,893 | -1,814 | -1,555 | -1,397 | -1,256 | -1,144 |
Shareholders' Equity | 456.23 | 527.17 | 747.01 | 429.17 | 326.2 | 419.48 |
Total Liabilities & Equity | 511.25 | 582.98 | 792.34 | 465.63 | 352.74 | 444.65 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 3.14 | 3.57 | 4.76 | 6.53 | 5.02 | 4.6 |
Net Cash (Debt) | 448.32 | 515.01 | 720.53 | 417.07 | 299.93 | 403.65 |
Net Cash Growth | -33.07% | -28.52% | 72.76% | 39.06% | -25.70% | 115.20% |
Net Cash Per Share | 6.75 | 7.75 | 11.19 | 8.61 | 6.40 | 9.42 |
Book Value | 456.23 | 527.17 | 747.01 | 429.17 | 326.2 | 419.48 |
Book Value Per Share | 6.86 | 7.94 | 11.60 | 8.86 | 6.96 | 9.78 |
Tangible Book Value | 429.04 | 499.98 | 719.82 | 401.98 | 299.01 | 392.29 |
Tangible Book Value Per Share | 6.45 | 7.53 | 11.18 | 8.30 | 6.38 | 9.15 |